Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Janaki Sharma received her medical degree from the University of Kansas. She completed her residency at the Montefiore Medical Center, where she also completed a fellowship in geriatric medicine and a fellowship in hematology and medical oncology. Her research and clinical interests include executing clinical trials to test novel therapeutics in prostate cancer, and identifying and targeting molecular drivers of prostate cancer. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Executing clinical trials to test novel therapeutics in prostate cancer Identifying and targeting molecular drivers of prostate cancer -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
“Urology on the Beach” Highlights Advances in Clinical Research and Innovative Technology
Sylvester K12 Symposium Brings Together Prior and New Award Winners
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 8 clinical trials.
-
We are doing this study because we want to find out if this approach is better or worse than the usual approach for your prostate cancer. The usual approach is defined as care most people get for prostate cancer.
- Principal Investigator: Janaki Sharma
- Study Phase: Phase III
- Enrollment Status: Open
-
A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
- Principal Investigator: Janaki Sharma
- Study Phase: Phase 1
- Enrollment Status: Closed
-
First-in-human, Dose Titration and Expansion Trial to Evaluate Safety, Immunogenicity and Preliminary Efficacy of W_pro1 (BNT112) Monotherapy and in Combination With Cemiplimab in Patients With Prostate Cancer
- Principal Investigator: Janaki Sharma
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
To investigate the dose combination-toxicity relationship and identify a potential set of Maximum Tolerated Dose (MTD) combinations (if reached) of M1774 in combination with M4076.
- Principal Investigator: Janaki Sharma
- Study Phase: Phase I
- Enrollment Status: Closed
-
To compare the ctDNA clearance proportion (i.e., ctDNA positive [+] --> ctDNA negative [-]) at 12 weeks in patients enrolled in Cohort A treated with adjuvant nivolumab versus nivolumab + relatlimab (phase 2 portion).
- Principal Investigator: Janaki Sharma
- Study Phase: Phase II/III
- Enrollment Status: Open
-
To evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with placebo plus nivolumab. To evaluate the safety of adjuvant treatment with autogene cevumeran plus nivolumab compared with placebo plus nivolumab To evaluate the participant-reported tolerability of adjuvant autogene cevumeran plus nivolumab compared with placebo plus nivolumab.
- Principal Investigator: Janaki Sharma
- Study Phase: Phase II
- Enrollment Status: Closed
-
This study is being done to learn more about how safe and effective xaluritamig is when compared to already approved standard treatments in people with prostate cancer that has spread to other parts of the body (also known as metastatic castration-resistant prostate cancer [mCRPC]) who have already been treated with chemotherapy.
- Principal Investigator: Janaki Sharma
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
The purpose of this study is to test the good and bad effects of the drug called M1774. M1774 could shrink your cancer, but it could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the study drug will stabilize or shrink your cancer.
- Principal Investigator: Janaki Sharma
- Study Phase: Phase II
- Enrollment Status: Not Accepting